subscribe
 

Amarin receives special protocol assessment agreement

Amarin announced that it has reached agreement with the U.S. FDA under a Special Protocol Assessment for its planned Phase 3 clinical trial of AMR101 in patients with mixed dyslipidemia.



Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe